MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma

Despite the improvement in clinical outcome with 13-cis-retinoic acid (13-cisRA) + anti-GD2 antibody + cytokine immunotherapy given in first response ~40% of high-risk neuroblastoma patients die of recurrent disease. MYCN genomic amplification is a biomarker of aggressive tumors in the childhood can...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cell Death Dis
Egile Nagusiak: Wei, Sung-Jen, Nguyen, Thinh H., Yang, In-Hyoung, Mook, Dustin G., Makena, Monish Ram, Verlekar, Dattesh, Hindle, Ashly, Martinez, Gloria M., Yang, Shengping, Shimada, Hiroyuki, Reynolds, C. Patrick, Kang, Min H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7224192/
https://ncbi.nlm.nih.gov/pubmed/32409685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2563-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak